ESMO Daily Reporter
Onco
Daily
Twitter
Facebook
Youtube
RSS Feed
Linkedin
Facebook
RSS
Twitter
Youtube
Linkedin
June, 2024
June 2024
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
« May
ESMO Daily Reporter
Jun 27, 2024, 09:10 |
Insight
The promise of immuno-oncology in the neoadjuvant setting - ESMO
The European Society for Medical Oncology (ESMO) shared on LinkedIn: “The promise of immuno-oncology in…
Jun 26, 2024, 13:47 |
Societies
177Lu-DOTATATE as a frontline treatment for somatostatin receptor-positive grade 3 low GEP-NETs
ESMO shared on LinkedIn: "ESMOGI24: Promising data from the phase III NETTER-2 study show that…
Jun 15, 2024, 07:40 |
Insight
Findings from a first-in-human phase I study investigating IBI363 - ESMO
ESMO shared on LinkedIn: "ESMO Virtual Plenary: Findings from a first-in-human phase I study investigating…
May 29, 2024, 04:01 |
Insight
ESMO Precision Medicine Working Group released NGS recommendations
ESMO shared on LinkedIn: "ESMO has just released recommendations for the use of next-generation sequencing (NGS)…
May 18, 2024, 01:12 |
Opinion
Results from the IMpassion132 trial presented at ESMO Breast 24
The European Society for Medical Oncology (ESMO) shared on LinkedIn: “Results from the IMpassion132 trial presented…
May 15, 2024, 13:47 |
Societies
Interview with Eric Van Cutsem and Zorana Maravic on the ESMO Daily Reporter - ESMO
The European Society for Medical Oncology (ESMO) shared on X: “While novel agents continue to…
Mar 1, 2024, 16:32 |
Blog
Yardena Samuels discusses how ongoing research is revisiting the classic neoantigen approach - The European Society for Medical Oncology (ESMO)
The European Society for Medical Oncology (ESMO) posted on LinkedIn: “ESMOTAT24: Novel antigens for cancer…
Oct 24, 2023, 14:57 |
Blog
ESMO updates from Presidential Symposium- European Society for Medical Oncology (ESMO)
European Society for Medical Oncology (ESMO) shared on LinkedIn: "Positive outcomes in advanced or metastatic…
All:
8
Posts:
1 - 10
Career Journey to President and CEO - OncoInfluencers
New Paper Alert! Long-Term Benefits of Dabrafenib-Trametinib in Stage III Melanoma: 8-Year COMBI-AD Trial Results
We mourn the loss of our Ivy Elkins
FDA grants accelerated approval to adagrasib with cetuximab for KRAS G12C-mutated colorectal cancer
Rob Winn: Honored to receive the ASCO Allen Lichter Visionary Leader Award
Facebook
RSS Feed
Twitter
Linkedin
Youtube